3.Congenital hydrocephalus : remaining clinical issues

Major Issues Remaining

Persistence and Discontinuation of Oral Anticoagulant: Remaining Issues Not Addressed by Phase III Clinical Trials

T here is general consensus that oral anticoagulant (OAC) therapy is recommended for stroke prevention in patients with atrial fibrillation (AF) and stroke risk factors. It is important to note that approximately one fourth of patients with AF who initiated OAC therapy (vitamin K antagonists including warfarin) discontinued it within the first year in real-world clinical practice. Since warfari...

Cell therapy for stroke: remaining issues to address before embarking on clinical trials.

BACKGROUND AND PURPOSE Stroke remains a significant clinical unmet condition, with only 3% of ischemic patient population benefiting from the thrombolytic drug tissue plasminogen activator largely because of the drug's narrow 3-hour therapeutic window. Extending the stroke therapeutic window will greatly impact on treatment, care, and management of patients. Summary of Review- Cell therapy is a...

3 Clinical Presentation of Hydrocephalus

In fetus, while minor degree of hydrocephalus often goes undetected, severe cases of obstructive variety present with the following features: 1 .the head is felt larger, globular and softer than the normal head 2.the head is high up and difficult to push down into pelvis 3.fetal heart sound is situated high up above the umbilicus 4.internal examination during labor may reveal widening of suture...

Internal thyroid doses to Fukushima residents—estimation and issues remaining

Enormous quantities of radionuclides were released into the environment following the disastrous accident at the Fukushima Daiichi Nuclear Power Plant (FDNPP) in March 2011. It is of great importance to determine the exposure doses received by the populations living in the radiologically affected areas; however, there has been significant difficulty in estimating the internal thyroid dose recei...